Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Jan
22
Today In Oncology
Limited or No State Regulation of STLD Health Plans Linked to Decreases in Timely Cancer Treatment Initiation
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
Regulatory Agencies Establish Principles of Good AI Use in Drug Development
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo